Investor Presentaiton slide image

Investor Presentaiton

Immunology LPA₁ Sotyktu CD19 NEX T First-in-class TYK2 inhibitor to treat PsO, with broad potential across PsA, SLE, SjS, and AA Today Psoriasis Sotyktu is approved for moderate-to-severe PSO and has reset the bar for oral treatments Near-Term Psoriatic Arthritis Leveraging strong relationship between PSO and PsA, sharing common pathogenic mechanisms1 Future Systemic Lupus Erythematosus, Sjögren's Syndrome, & Alopecia Areata Disruptive potential in SLE and new opportunity in SjS given similar disease pathogenesis Potential in AA based on inhibition of the IL-12/IFNY axis² Oral, tolerable, mechanistically differentiated TYK-2 targeting agent provides broad applicability across a range of immune-mediated diseases 1. Mease PJ, Armstrong AW. Drugs. 2014;74:423-441. 2. Edelkamp J, et al. ESDR 2022 [poster presentation]. Bristol Myers Squibb™ Not for Product Promotional Use 67
View entire presentation